News
OCX
2.500
-2.34%
-0.060
Oncocyte Price Target Maintained With a $4.00/Share by Stephens & Co.
Dow Jones · 2d ago
Stephens & Co. Reiterates Equal-Weight on OncoCyte, Maintains $4 Price Target
Benzinga · 2d ago
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. The company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome. Soligenix, Inc. Shares surged 71.5% after the company was granted orphan drug designation for MarVax.
Benzinga · 4d ago
NXPL, MGRM and OCX among pre-market losers
U.S. Economy NXPL, MGRM and OCX among pre-market losers. Marinus Pharmaceuticals -74% provides update on the phase 3 RAISE trial. NextPlat Corp -19% as FDA puts Phase 1 schizophrenia study on hold.
Seeking Alpha · 4d ago
Weekly Report: what happened at OCX last week (0408-0412)?
Weekly Report · 4d ago
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Medical Properties Trust, Inc. Shares jumped 13.1% in today's pre-market trading. The company announced it sold its majority interest in Utah Hospitals. LendingClub Corporation is expected to report earnings for the first quarter 2024 after the closing bell on Tuesday. Allarity Therapeutics shares rose 51% to $3.17 in pre- market trading.
Benzinga · 5d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. Allarity Therapeutics stock rose 18.09% and Galecto stock increased by 5.58%. PaxMedica stock declined by 8.0% during the session.
Benzinga · 04/12 20:31
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023
OncoCyte reported results for the fourth quarter of 2023. The company reported earnings per share of -$2.18 and revenue of $314,000. This was below the analyst estimate for earnings of $1.14 and $320,000 in revenue.
Investorplace · 04/12 14:52
OncoCyte Corp reports results for the quarter ended in December - Earnings Summary
OncoCyte Corp reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $2.12 per share. Revenue fell 72% to $314.00 thousand from a year ago. The average analyst rating on the company's shares is "hold"
Reuters · 04/12 13:31
S&P Futures Tick Lower as Investors Digest Big Bank Earnings
NASDAQ · 04/12 13:23
Top 3 Health Care Stocks That May Collapse In Q2
Three stocks in the health care sector are overbought as of April 12, 2024. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength when they go down. An asset is typically considered to be overb bought when the RSI value is above 70.
Benzinga · 04/12 12:34
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Friday is the final day of trading this week. PaxMedica stock is rocketing close to 82% after hitting a key milestone in drug development. The biggest pre-market stock movers this morning are earnings reports, stakeholder updates, drug development news and more.
Investorplace · 04/12 11:29
Earnings Scheduled For April 12, 2024
Progressive is projected to report quarterly earnings at $3.17 per share on revenue of $17.43 billion. Citigroup and State Street are expected to report before the bell. JPMorgan Chase and BlackRock are likely to report after the bell as well. KULR Tech Gr is expected to post quarterly loss at $0.04.
Benzinga · 04/12 11:17
S&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank Earnings
NASDAQ · 04/12 11:11
Oncocyte GAAP EPS of -$3.37 misses by $0.87, revenue of $1.5M misses by $0.01M
OncoCyte Corporation's FY GAAP EPS of -$3.37 misses by $0.87, revenue of $1.5M misses by $ 0.01M. Oncocyte to report quarterly results on April 12. The company is expected to report Q1 results on May 1.
Seeking Alpha · 04/12 10:32
OncoCyte Corp Announces Equity Placement and Fundraising Efforts
TipRanks · 04/12 10:22
OncoCyte Q4 EPS $(2.18) Misses $(1.14) Estimate, Sales $314.00K Miss $316.67K Estimate
Benzinga · 04/12 10:07
*Oncocyte 4Q Loss From Operations $16.2M >OCX
Dow Jones · 04/12 10:05
*Oncocyte 4Q Rev $314,000 >OCX
Dow Jones · 04/12 10:01
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
Reuters · 04/12 10:00
More
Webull provides a variety of real-time OCX stock news. You can receive the latest news about Oncocyte Corporation through multiple platforms. This information may help you make smarter investment decisions.
About OCX
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, and DetermaCNI. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor, combined with information from the wound response surrounding the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test.